Liver Disease Therapeutics
•12 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (12)
| Company | Market Cap | Price |
|---|---|---|
|
GILD
Gilead Sciences, Inc.
Livdelzi (seladelpar) targets liver disease (PBC), aligning with Liver Disease Therapeutics.
|
$146.63B |
$118.38
+0.42%
|
|
MDGL
Madrigal Pharmaceuticals, Inc.
Liver disease therapeutics is a broad, investable theme that encompasses the NAFLD/NASH treatment market, which Madrigal targets with Rezdiffra.
|
$9.53B |
$421.61
-1.76%
|
|
VKTX
Viking Therapeutics, Inc.
VK2809 is a liver-selective TRβ agonist targeting NASH/fibrosis, a liver disease therapeutics program.
|
$3.93B |
$35.20
+0.77%
|
|
MIRM
Mirum Pharmaceuticals, Inc.
Core business includes liver disease therapeutics, with LIVMARLI and CTEXLI and acquired bile acid medications.
|
$3.49B |
$70.95
+0.62%
|
|
KRRO
Korro Bio, Inc.
Delivery approach GalNAc liver-targeting implies liver disease/hepatic targeting therapeutics.
|
$376.37M |
$38.66
-3.56%
|
|
DCTH
Delcath Systems, Inc.
Platform aims to treat liver-dominant cancers, aligning with the Liver Disease Therapeutics investable theme.
|
$353.49M |
$9.79
-3.50%
|
|
SLN
Silence Therapeutics plc
Divesiran targets pathways related to liver iron metabolism and PV, aligning with liver disease therapeutics.
|
$344.80M |
$7.17
-1.92%
|
|
IVA
Inventiva S.A.
Lanifibranor targets a liver-disease indication (MASH/NASH), aligning with the 'Liver Disease Therapeutics' tag.
|
$276.55M |
$4.23
-19.73%
|
|
GNFT
Genfit S.A.
GENFIT's ELAFIBRONOR in Primary Biliary Cholangitis (PBC) represents a core liver-disease therapeutic offering.
|
$209.61M |
N/A
|
|
KZR
Kezar Life Sciences, Inc.
Kezar’s AIH program targets a liver disease indication, fitting the Liver Disease Therapeutics theme.
|
$45.66M |
$6.21
-0.72%
|
|
SBFM
Sunshine Biopharma, Inc.
K1.1 mRNA liver cancer program places the company in liver disease therapeutics.
|
$8.38M |
$1.76
-4.35%
|
|
CANF
Can-Fite BioPharma Ltd.
Namodenoson targets liver disease indications (NAFLD/NASH and hepatocellular carcinoma).
|
$2.31M |
$0.43
-5.86%
|
Loading industry trends...
Loading research report...
